IMM-20059
Product Specifications
Bioactivity
IMM-20059 is a humanized IgG1 monoclonal antibody targeting EPN1. When combined with Atezolizumab, IMM-20059 significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog